JP2017517579A5 - - Google Patents

Info

Publication number

JP2017517579A5

JP2017517579A5 JP2017517441A JP2017517441A JP2017517579A5 JP 2017517579 A5 JP2017517579 A5 JP 2017517579A5 JP 2017517441 A JP2017517441 A JP 2017517441A JP 2017517441 A JP2017517441 A JP 2017517441A JP 2017517579 A5 JP2017517579 A5 JP 2017517579A5

Authority

JP

Japan

Prior art keywords

therapeutic agent

agent according

thieno

triazolo

trimethyl

Prior art date

2015-06-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims description 23
• 150000001875 compounds Chemical class 0.000 claims description 19
• 239000007962 solid dispersion Substances 0.000 claims description 11
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 8
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 8
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
• 229940079593 drug Drugs 0.000 claims description 7
• 229920000642 polymer Polymers 0.000 claims description 7
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
• GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims description 6
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
• 150000003839 salts Chemical class 0.000 claims description 6
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
• 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims description 5
• 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 5
• 229940124302 mTOR inhibitor Drugs 0.000 claims description 5
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 5
• 229960005167 everolimus Drugs 0.000 claims description 4
• 239000003112 inhibitor Substances 0.000 claims description 4
• 241000124008 Mammalia Species 0.000 claims description 3
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 3
• 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 2
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical group O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 2
• 229960005061 crizotinib Drugs 0.000 claims description 2
• 230000009477 glass transition Effects 0.000 claims description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
• 229960002930 sirolimus Drugs 0.000 claims description 2
• 229960000235 temsirolimus Drugs 0.000 claims description 2
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 2
• 229940124597 therapeutic agent Drugs 0.000 claims 16
• 239000003795 chemical substances by application Substances 0.000 claims 4
• 239000006185 dispersion Substances 0.000 claims 1
• 210000004072 lung Anatomy 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 238000000034 method Methods 0.000 description 24
• 125000004432 carbon atom Chemical group C* 0.000 description 22
• 125000000217 alkyl group Chemical group 0.000 description 16
• 125000005843 halogen group Chemical group 0.000 description 12
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
• 125000003545 alkoxy group Chemical group 0.000 description 6
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• -1 Methyl (S)-{4- (3′-cyanobiphenyl-4-yl) -2,3,9-trimethyl-6H-thieno [3,2-f] [1,2,4] triazolo [ 4,3-a] [1,4] diazepin-6-yl} acetate Chemical compound 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 125000004093 cyano group Chemical group *C#N 0.000 description 2
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1